Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Boehringer’s Survodutide Makes Mark in Japan PIII Obesity Trial
Nippon Boehringer Ingelheim said on October 5 that its GLP-1/glucagon receptor agonist survodutide (BI 456906) met the primary endpoints in the PIII SYNCHRONIZE-JP trial, delivering significant weight reductions in Japanese patients with obesity. The study tested once-weekly survodutide at doses…
To read the full story
Related Article
- Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
September 28, 2026
BUSINESS
- Boehringer’s Survodutide Makes Mark in Japan PIII Obesity Trial
October 6, 2026
- Kyowa Finds Nitrosamines in 2 Antidepressants; No Recall Planned
October 6, 2026
- Nippon Zoki Bags Japan Rights to Taiwan Firm’s Knee Osteoarthritis Drug
October 6, 2026
- AstraZeneca, Academic Society Join Hands on Obesity Care in Japan
October 6, 2026
- Daiichi Sankyo to Take Sole Charge of Emgality Information Activities
October 6, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…